GPP
CPRX icon

Great Point Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Great Point Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,695,742
Closed -$6.44M – 39
2018
Q1 		$6.44M Sell
2,695,742
-1,121,546
-29% -$3.73M 0.96% 24
2017
Q4 		$14.9M Buy
+3,817,288
New +$12.6M 2.55% 18

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Great Point Partners's CPRX Position: Q2 2018 in Review

Great Point Partners sold out of Catalyst Pharmaceutical (CPRX) in Q2 2018, closing a stake of 2,695,742 shares — an estimated $6.44M sold.

Great Point Partners first reported a position in CPRX in Q4 2017 and held it in 2 quarters. The position peaked at $14.9M in Q4 2017. 99 funds tracked by Wall St. Rank hold CPRX as of Q2 2018.

  • Great Point Partners reported no remaining Catalyst Pharmaceutical position as of Q2 2018 after selling out during the quarter.
  • Great Point Partners sold 2,695,742 Catalyst Pharmaceutical shares in Q2 2018, an estimated $6.44M.
  • Great Point Partners first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 2 quarters.
  • Great Point Partners's Catalyst Pharmaceutical position peaked at $14.9M in Q4 2017.
  • 99 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2018.

Based on Great Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.